NCT04701658View on ClinicalTrials.gov

A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

PHASE2CompletedINTERVENTIONAL

Enrollment

109

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

June 22, 2021

Study Completion Date

June 22, 2021

Conditions

COVID-19

Interventions

DRUG

Bamlanivimab

Administered intravenously.

Trial Locations (1)

87110

Presbyterian Medical Center, Albuquerque

Sponsors

Collaborators (1)

AbCellera Biologics Inc.

All Listed Sponsors

collaborator

AbCellera Biologics Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT04701658 - A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19) | Biotech Hunter | Biotech Hunter